Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors

Gene Therapy

Volumn 17, Issue 7, 2010, Pages 872-879

  Zeltner, N ^a   Kohlbrenner, E ^a   Clement N ^b   Weber, T ^a   Linden, R M ^a,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

particle to infectivity ratio; rAAV; specific activity; wtAAV

Indexed keywords

PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ARTICLE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS PURIFICATION; VIRUS RECOMBINANT; WILD TYPE; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETIC ENGINEERING; GENETIC RECOMBINATION; GENETICS; PATHOGENICITY; PROCEDURES; STANDARDS; VIRION;

DEPENDOVIRUS; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; GENOME, VIRAL; RECOMBINATION, GENETIC; VIRION; GENETIC THERAPY;

ADENO-ASSOCIATED VIRUS;

EID: 77954537926     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.27     Document Type: Article

References (27)

1. Buch PK, Bainbridge JW, Ali RR. AAV-mediated gene therapy for retinal disorders: from mouse to man. Gene Ther 2008; 15: 849-857.
2. Cecchini S, Negrete A, Kotin RM. Toward exascale production of recombinant adeno-associated virus for gene transfer applications. Gene Ther 2008; 15: 823-830.
3. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007; 13: 419-422.
4. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
5. Hauck B, Murphy SL, Smith PH, Qu G, Liu X, Zelenaia O et al. Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses. Mol Ther 2009; 17: 144-152.
6. Salvetti A, Oreve S, Chadeuf G, Favre D, Cherel Y, Champion-Arnaud P et al. Factors influencing recombinant adeno-associated virus production. Hum Gene Ther 1998; 9: 695-706.
7. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999; 6: 973-985.
8. Debelak D, Fisher J, Iuliano S, Sesholtz D, Sloane DL, Atkinson EM. Cation-exchange high-performance liquid chromatography of recombinant adeno-associated virus type 2. J Chromatogr B Biomed Sci Appl 2000; 740: 195-202.
9. Zen Z, Espinoza Y, Bleu T, Sommer JM, Wright JF. Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events. Hum Gene Ther 2004; 15: 709-715.
10. Sommer JM, Smith PH, Parthasarathy S, Isaacs J, Vijay S, Kieran J et al. Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Mol Ther 2003; 7: 122-128.
11. Qu G, Bahr-Davidson J, Prado J, Tai A, Cataniag F, McDonnell J et al. Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. J Virol Methods 2007; 140: 183-192.
12. Grimm D, Kern A, Pawlita M, Ferrari F, Samulski R, Kleinsch-midt J. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther 1999; 6: 1322-1330.
13. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 1998; 9: 2745-2760.
14. Grieger JC, Choi VW, Samulski RJ. Production and characterization of adeno-associated viral vectors. Nat Protoc 2006; 1: 1412-1428.
15. Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR. Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther 1995; 6: 1329-1341.
16. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70: 3227-3234.
17. Fisher KJ, Gao GP, Weitzman MD, DeMatteo R, Burda JF, Wilson JM. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996; 70: 520-532.
18. Rohr UP, Wulf MA, Stahn S, Steidl U, Haas R, Kronenwett R. Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR. J Virol Methods 2002; 106: 81-88.
19. Xie Q, Bu W, Bhatia S, Hare J, Somasundaram T, Azzi A et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 10405-10410.
20. Urabe M, Ding C, Kotin RM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 2002; 13: 1935-1943.
21. Tullis GE, Shenk T. Efficient replication of adeno-associated virus type 2 vectors: a cis-acting element outside of the terminal repeats and a minimal size. J Virol 2000; 74: 11511-11521.
22. Ward P, Clement N, Linden RM. cis effects in adeno-associated virus type 2 replication. J Virol 2007; 81: 9976-9989.
23. Nony P, Tessier J, Chadeuf G, Ward P, Giraud A, Dugast M et al. Novel cis-acting replication element in the adeno-associated virus type 2 genome is involved in amplification of integrated rep-cap sequences. J Virol 2001; 75: 9991-9994.
24. Francois A, Guilbaud M, Awedikian R, Chadeuf G, Moullier P, Salvetti A. The cellular TATA binding protein is required for rep-dependent replication of a minimal adeno-associated virus type 2 p5 element. J Virol 2005; 79: 11082-11094.
25. Zhou X, Muzyczka N. In vitro packaging of adeno-associated virus DNA. J Virol 1998; 72: 3241-3247.
26. Myers MW, Carter BJ. Assembly of adeno-associated virus. Virology 1980; 102: 71-82.
27. Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, Tsien RY. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 2004; 22: 1567-1572.